These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

698 related articles for article (PubMed ID: 17000960)

  • 1. Is late-onset multiple sclerosis associated with a worse outcome?
    Tremlett H; Devonshire V
    Neurology; 2006 Sep; 67(6):954-9. PubMed ID: 17000960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of secondary-progressive multiple sclerosis.
    Tremlett H; Yinshan Zhao ; Devonshire V
    Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disability progression in multiple sclerosis is slower than previously reported.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2006 Jan; 66(2):172-7. PubMed ID: 16434648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of gender on late-onset multiple sclerosis.
    Bove RM; Healy B; Augustine A; Musallam A; Gholipour T; Chitnis T
    Mult Scler; 2012 Oct; 18(10):1472-9. PubMed ID: 22383227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The natural history of primary progressive multiple sclerosis.
    Koch M; Kingwell E; Rieckmann P; Tremlett H
    Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The natural history of primary progressive MS in British Columbia, Canada.
    Tremlett H; Paty D; Devonshire V
    Neurology; 2005 Dec; 65(12):1919-23. PubMed ID: 16380613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Older Age at Multiple Sclerosis Onset Is an Independent Factor of Poor Prognosis: A Population-Based Cohort Study.
    Guillemin F; Baumann C; Epstein J; Kerschen P; Garot T; Mathey G; Debouverie M;
    Neuroepidemiology; 2017; 48(3-4):179-187. PubMed ID: 28793296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the natural history and prognostic features of early onset and adult onset multiple sclerosis in Jordanian population.
    El-Salem K; Khader Y
    Clin Neurol Neurosurg; 2007 Jan; 109(1):32-7. PubMed ID: 16870328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical profile and HLA-DRB1 genotype of late onset multiple sclerosis in Western Australia.
    Qiu W; Wu JS; Castley A; James I; Joseph J; Christiansen FT; Carroll WM; Mastaglia FL; Kermode AG
    J Clin Neurosci; 2010 Aug; 17(8):1009-13. PubMed ID: 20580995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts.
    Kingwell E; Leung AL; Roger E; Duquette P; Rieckmann P; Tremlett H;
    J Neurol Sci; 2010 May; 292(1-2):57-62. PubMed ID: 20202651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Late onset multiple sclerosis].
    Delalande S; De Seze J; Ferriby D; Stojkovic T; Vermersch P
    Rev Neurol (Paris); 2002 Nov; 158(11):1082-7. PubMed ID: 12451340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis.
    Mirmosayyeb O; Brand S; Barzegar M; Afshari-Safavi A; Nehzat N; Shaygannejad V; Sadeghi Bahmani D
    J Clin Med; 2020 May; 9(5):. PubMed ID: 32370288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of HLA-DRB1 alleles on susceptibility and outcome of a Portuguese Multiple Sclerosis population.
    Silva AM; Pereira C; Bettencourt A; Carvalho C; Couto AR; Leite MI; Marta M; Freijo M; Costa PP; Mendonça D; Monteiro L; Armas JB; Martins B
    J Neurol Sci; 2007 Jul; 258(1-2):69-74. PubMed ID: 17412364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late-onset multiple sclerosis in Isfahan, Iran.
    Etemadifar M; Abtahi SH; Minagar A; Akbari M; Masaeli A; Tabrizi N
    Arch Iran Med; 2012 Oct; 15(10):596-8. PubMed ID: 23020533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
    Mouresan EF; Mentesidou E; Berglund A; McKay KA; Hillert J; Iacobaeus E
    Neurology; 2024 Mar; 102(6):e208051. PubMed ID: 38394472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Time to Reach EDSS 6.0 Faster in Patients with Late-Onset versus Young-Onset Multiple Sclerosis?
    Alroughani R; Akhtar S; Ahmed S; Behbehani R; Al-Hashel J
    PLoS One; 2016; 11(11):e0165846. PubMed ID: 27802328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical course of multiple sclerosis patients in Hong Kong.
    Lau KK; Wong WW; Sheng B; Yu IT; Fung BH; Li HL; Ma KF; Wong LK; Li PC
    J Neurol Sci; 2008 May; 268(1-2):78-82. PubMed ID: 18068191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple sclerosis in older adults: the clinical profile and impact of interferon Beta treatment.
    Shirani A; Zhao Y; Petkau J; Gustafson P; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Tremlett H
    Biomed Res Int; 2015; 2015():451912. PubMed ID: 25922836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica.
    Ghezzi A; Bergamaschi R; Martinelli V; Trojano M; Tola MR; Merelli E; Mancardi L; Gallo P; Filippi M; Zaffaroni M; Comi G;
    J Neurol; 2004 Jan; 251(1):47-52. PubMed ID: 14999489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.